Notice NOT-OD-23-129 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-206 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).
Funding Opportunity PAR-23-198 from the NIH Guide for Grants and Contracts. The NIAID New Innovator Award supports a postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.
Notice NOT-OD-23-134 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-136 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-135 from the NIH Guide for Grants and Contracts
Notice NOT-MH-23-240 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-24-120 from the NIH Guide for Grants and Contracts. The goal of this phased FOA (either R33/R61 or UG3/UH3) is to accelerate the development of sensitive biomarkers/tools to predict individual treatment-response between two or more existing treatments for depression. In phase 1 (up to 2 years) preliminary studies (e.g., retrospective secondary analyses of data from completed clinical trials and/or in nimble, fast-fail pilot studies) will de-risk the test technology demonstrating that there is enough signal for clinical utility (futility analyses, ROC curves, and/or effect size will be evaluated as go/no-go criteria). Phase 2 (up to 5 years) innovators will prospectively test the efficacy of the biomarker/tool in large-scale biomarker/tool-stratified clinical trials with the goal of beating standard-of-care decision-making (i.e., clinician/patient treatment assignment will be the CTRL group vs the test).
Funding Opportunity PAR-23-166 from the NIH Guide for Grants and Contracts. The purpose of theNative American Research Centers for Health (NARCH) program is to fund federally-recognized American Indian/Alaska Native (AI/AN) tribes and tribal organizations to support health-related research, research career enhancement, and research infrastructure enhancement activities.
Study seeks to identify promising treatments that can advance to larger, more definitive clinical trials
Notice NOT-EB-23-009 from the NIH Guide for Grants and Contracts
Notice NOT-MH-23-265 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-022 from the NIH Guide for Grants and Contracts
Genome sequencing reveals genetic basis for disabling pansclerotic morphea, a severe inflammatory disease.
Funding Opportunity RFA-DK-23-013 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDDK R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. This FOA solicits applications to establish summer research institutes for qualified undergraduates to participate in summer research experiences relevant to the mission of the Division of Kidney, Urologic and Hematologic Diseases/NIDDK (NIDDK/DKUH).
Funding Opportunity RFA-CA-23-024 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO), issued by the National Cancer Institute (NCI), is to invite competing continuation applications for cooperative agreement awards from current recipients of the NCI-supported Cooperative Human Tissue Network (CHTN). CHTN with all individual CHTN recipients (referred to as CHTN Divisions) collectively form the CHTN national resource. Presently, the organizational structure of the Network comprises six Divisions. The goal of the CHTN is to collect and distribute to investigators high-quality human tissue specimens to facilitate basic and translational cancer research. Such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, and prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on the prospective collection and distribution of samples upon specific investigators requests. Samples to be collected from patients include pre-cancerous, malignant, and benign neoplastic tissues, as well as tissues with non-neoplastic diseases and normal tissues. Since its establishment by the NCI in 1987, the CHTN has provided more than 1,350,000 malignant, benign, diseased, and uninvolved (normal adjacent) high-quality human tissue specimens from a wide variety of organ sites to over four thousand investigators.
Notice NOT-OD-23-137 from the NIH Guide for Grants and Contracts
Notice NOT-MD-23-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-24-032 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to further our understanding of how different behavioral, social, cultural, environmental, and institutional factors affect the trajectory of cognitive aging and Alzheimers disease (AD) and AD-related dementias (AD/ADRD) and the experience of living with or managing AD/ADRD in different national or regional contexts. Specifically, NIA seeks to support analyses of data from the Harmonized Cognitive Assessment Protocol (HCAP) from the US or another country where HCAP data is available or to perform cross-national analyses.
Notice NOT-HG-23-045 from the NIH Guide for Grants and Contracts